Показать сокращенную информацию
dc.contributor.author | Sokolova T.N. | |
dc.contributor.author | Aleksakhina S.N. | |
dc.contributor.author | Yanus G.A. | |
dc.contributor.author | Sultanbaev A.V. | |
dc.contributor.author | Menshikov K.V. | |
dc.contributor.author | Lysenko A.N. | |
dc.contributor.author | Zukov R.A. | |
dc.contributor.author | Zyuzyukina A.V. | |
dc.contributor.author | Murunova Y.N. | |
dc.contributor.author | Rossokha E.I. | |
dc.contributor.author | Bakharev S.Y. | |
dc.contributor.author | Basova E.A. | |
dc.contributor.author | Kasmynina T.A. | |
dc.contributor.author | Shumskaya I.S. | |
dc.contributor.author | Bakshun Y.I. | |
dc.contributor.author | Musaeva K.S. | |
dc.contributor.author | Khasanova A.I. | |
dc.contributor.author | Dmitriev V.N. | |
dc.contributor.author | Bolieva M.B. | |
dc.contributor.author | Gadzaova C.H. | |
dc.contributor.author | Petrenko O.L. | |
dc.contributor.author | Maksimov D.A. | |
dc.contributor.author | Vladimirov V.I. | |
dc.contributor.author | Goldberg V.E. | |
dc.contributor.author | Popova N.O. | |
dc.contributor.author | Kibisheva M.V. | |
dc.contributor.author | Khamgokov Z.M. | |
dc.contributor.author | Vasilyev A.E. | |
dc.contributor.author | Iyevleva A.G. | |
dc.contributor.author | Imyanitov E.N. | |
dc.date.accessioned | 2022-02-09T20:49:09Z | |
dc.date.available | 2022-02-09T20:49:09Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 2560-6921 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/170505 | |
dc.description.abstract | Relevance. PIK3CA belongs to the top three most frequently mutated genes in breast cancer (BC), especially in estrogen recep-tor (ER) positive, HER2 negative BC subtype. With an approval of selective PI3K-alpha inhibitor, alpelisib, this alteration has beco-me actionable in ER tumors. The frequency and spectrum of PIK3CA alterations in various cohorts is affected by a number of factors, including the distribution of BC expression subtypes, histological types, patient age, and even ethnicity. Aim. Aim of the current study was to characterize the frequency and spectrum of PIK3CA alterations in Russian BC patients. Materials and methods. The analysis of PIK3CA exon 7, 9 and 20 mutations was performed in a cohort of Russian ER BC patients by a combination of high-resolution melting analysis, allele-specific PCR, and digital droplet PCR. Results. PIK3CA lesions were identified in 62/206 (30%) patients. Noteworthy, 59/62 (95%) of the identified variants were repre-sented by the three most common p.E542K, p.E545K, and p.H1047R substitutions. The analysis of clinical and morphological cha-racteristics revealed the trends towards association of PIK3CA mutations with older age and more frequent metastatic lung in-volvement. Conclusion. The obtained data on the frequency and spectrum of PIK3CA somatic aberrations can be helpful when organizing molecular genetic testing of breast cancer patients and using PI3K inhibitors in Russian population. | |
dc.relation.ispartofseries | Journal of Nonlinear and Variational Analysis | |
dc.subject | Alpelisib | |
dc.subject | Breast cancer | |
dc.subject | Mutations | |
dc.subject | PIK3CA | |
dc.title | The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 3 | |
dc.relation.ispartofseries-volume | 5 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 61 | |
dc.source.id | SCOPUS25606921-2021-5-3-SID85107273173 |